Differentiation Therapy "A Breakthrough for Cancer"Lalitha Ambighai
Differentiation Therapy has built a unique bridge between cell proliferation and differentiation for malignant cells which gave hope for researches in finding cure for cancers.
These slides shows a summation of a pre-done video in explaining differentiation therapy and its clinical applications specifically on pediatric neuroblastoma and acute promyelocytic leukemia.
All information in slides were obtained from external sources as in the citation and reference list.
*Slides prepared by: Anna Mayr, Lalitha Ambighai, Cheah Toh Yang, Romel Mario Soyza, Gayathri Nanayakkara and Stephanie Veter*
P.S Comments and questions in regards to researched topic would be very much welcomed and appreciated. Thank you. Have a nice day. :)
Differentiation Therapy "A Breakthrough for Cancer"Lalitha Ambighai
Differentiation Therapy has built a unique bridge between cell proliferation and differentiation for malignant cells which gave hope for researches in finding cure for cancers.
These slides shows a summation of a pre-done video in explaining differentiation therapy and its clinical applications specifically on pediatric neuroblastoma and acute promyelocytic leukemia.
All information in slides were obtained from external sources as in the citation and reference list.
*Slides prepared by: Anna Mayr, Lalitha Ambighai, Cheah Toh Yang, Romel Mario Soyza, Gayathri Nanayakkara and Stephanie Veter*
P.S Comments and questions in regards to researched topic would be very much welcomed and appreciated. Thank you. Have a nice day. :)
Outcomes of Fibrinolytic Therapy Versus PCIPeachy Essay
Several studies have been conducted to analyze the relative benefits of Percutaneous Coronary Intervention (PCI) and fibrinolytic therapy in the treatment of ST-Segment Elevation Myocardial Infarction (STEMI). The timely severity associated with STEMI has made it essential to identify the better of the two interventions. A successful intervention of STEMI depends on the thorough decision to either use PCI or fibrinolytic therapy. A study was conducted by Armstrong et al. (2013), comparing fibrinolytic therapy and primary PCI; a randomized control trial was administered to a sample of 1892 patients. The patients
underwent either fibrinolytic therapy or primary PCI, within 3 hours of presentation of symptoms of STEMI. The assigning of the patients to either undergo fibrinolytic therapy and primary PCI was done randomly.
Denosumab is a potent monoclonal antibody which inactivates
the RANK ligand. Inactivation of RANK ligand leads to the
inhibition of osteoclast activity and maturation which decreases
bone resorption. Denosumab is a potent antiresorptive that has been shown to dramatically suppress bone turnover markers, maintain bone mineral density, and prevent fractures
Denosumab is a potent monoclonal antibody which inactivates
the RANK ligand. Inactivation of RANK ligand leads to the
inhibition of osteoclast activity and maturation which decreases
bone resorption. Denosumab is a potent antiresorptive that has been shown to dramatically suppress bone turnover markers, maintain bone mineral density, and prevent fractures
Predictive value of exercise myocardial perfusion imaging in the Medicare population: the impact of the ability to exercise
Authors: Deborah H. Kwon, Venu Menon, Penny Houghtaling, Elizabeth Lieber, Richard C. Brunken, Manuel D. Cerqueira, Wael A. Jaber
Effects of aspirin for primary prevention in persons with Diabetes mellitusShadab Ahmad
The ASCEND(A Study od Cardiovascular Events in Diabetes) randomized trial was performed to assess the efficacy and safety of enteric-coated aspirin at a dose of 100 mg daily, as compared with placebo, in person who had diabetes without manifest cardiovascular disease.
Presentation from Indie Group Spring Camp (March 2011), including presentation from Minister Vincent Van Quickenborne, Cis Scherpereel (Indie Group), bPost and Multisafepay.
Gracias al Dr. Lorenzo Alonso, promotor, impulsor y alma mater del Foro Osler (https://www.facebook.com/foroosler?fref=ts) por esta magnífica presentación.
Outcomes of Fibrinolytic Therapy Versus PCIPeachy Essay
Several studies have been conducted to analyze the relative benefits of Percutaneous Coronary Intervention (PCI) and fibrinolytic therapy in the treatment of ST-Segment Elevation Myocardial Infarction (STEMI). The timely severity associated with STEMI has made it essential to identify the better of the two interventions. A successful intervention of STEMI depends on the thorough decision to either use PCI or fibrinolytic therapy. A study was conducted by Armstrong et al. (2013), comparing fibrinolytic therapy and primary PCI; a randomized control trial was administered to a sample of 1892 patients. The patients
underwent either fibrinolytic therapy or primary PCI, within 3 hours of presentation of symptoms of STEMI. The assigning of the patients to either undergo fibrinolytic therapy and primary PCI was done randomly.
Denosumab is a potent monoclonal antibody which inactivates
the RANK ligand. Inactivation of RANK ligand leads to the
inhibition of osteoclast activity and maturation which decreases
bone resorption. Denosumab is a potent antiresorptive that has been shown to dramatically suppress bone turnover markers, maintain bone mineral density, and prevent fractures
Denosumab is a potent monoclonal antibody which inactivates
the RANK ligand. Inactivation of RANK ligand leads to the
inhibition of osteoclast activity and maturation which decreases
bone resorption. Denosumab is a potent antiresorptive that has been shown to dramatically suppress bone turnover markers, maintain bone mineral density, and prevent fractures
Predictive value of exercise myocardial perfusion imaging in the Medicare population: the impact of the ability to exercise
Authors: Deborah H. Kwon, Venu Menon, Penny Houghtaling, Elizabeth Lieber, Richard C. Brunken, Manuel D. Cerqueira, Wael A. Jaber
Effects of aspirin for primary prevention in persons with Diabetes mellitusShadab Ahmad
The ASCEND(A Study od Cardiovascular Events in Diabetes) randomized trial was performed to assess the efficacy and safety of enteric-coated aspirin at a dose of 100 mg daily, as compared with placebo, in person who had diabetes without manifest cardiovascular disease.
Presentation from Indie Group Spring Camp (March 2011), including presentation from Minister Vincent Van Quickenborne, Cis Scherpereel (Indie Group), bPost and Multisafepay.
Gracias al Dr. Lorenzo Alonso, promotor, impulsor y alma mater del Foro Osler (https://www.facebook.com/foroosler?fref=ts) por esta magnífica presentación.
Here is a story of Mr. Mansukhbhai Raghavbhai Prajapati; who was a poor potter from Wandaner, Gujarat. But, with his preservation, resilience & passion for his ancestral work; pottery. This craftsman struggles across life’s barriers to become a leader who drove the socio-economic development in his state Gujarat and led to be country’s most known rural entrepreneur.
Here is a story of Mr. Mansukhbhai Raghavbhai Prajapati; who was a poor potter from Wandaner, Gujarat. But, with his preservation, resilience & passion for his ancestral work; pottery. This craftsman struggles across life’s barriers to become a leader who drove the socio-economic development in his state Gujarat and led to be country’s most known rural entrepreneur.
Afsluitende presentatie van de studieavond rond omni channel, Kulak, Kortrijk, 9/12/2014 door Cis Scherpereel, Consultant Online Ondernemen bij Indie Group
Presentatie van Cis Scherpereel (e-coach bij Indie Group) en Antoon Schockaert (Jurist, Unizo) rond de aspecten die een webshop tot een succesverhaal kunnen maken.
A Paradigm Shift in the Utilization of Therapeutic Plasmapheresis in Clinical...semualkaira
Therapeutic Plasma Exchange (TPE), frequently referred to as
plasmapheresis. is an automated procedure which separates whole
blood into plasma and blood cells. The plasma is discarded and
replaced with physiologic fluids and returned to the patient along
with the blood cells. Theoretically, any disease in which a humoral
phase is implicated in the pathogenesis may be at least partially
mitigated by removal of the patient’s plasma and replacement with
physiologic solutions. In clinical practice, TPE is used in a hospital
setting, usually as a last resort, to treat autoimmune diseases by removing circulating antibodies and/or immune complexes. Recently, it was demonstrated that TPE has several immunoregulatory
properties besides removal of circulating antibodies and immune
complexes. Both controlled and uncontrolled clinical studies have
demonstrated that TPE is associated with only a few mild adverse
reactions and can be performed safely in an outpatient setting.
We report our experience in treating patients with TPE on an outpatient basis with several different medical conditions (Alzheimer’s disease, Long Covid, PANDAS) and prophylactically in older
individuals for the attenuation of inflammaging
A Paradigm Shift in the Utilization of Therapeutic Plasmapheresis in Clinical...semualkaira
Therapeutic Plasma Exchange (TPE), frequently referred to as
plasmapheresis. is an automated procedure which separates whole
blood into plasma and blood cells. The plasma is discarded and
replaced with physiologic fluids and returned to the patient along
with the blood cells. Theoretically, any disease in which a humoral
phase is implicated in the pathogenesis may be at least partially
mitigated by removal of the patient’s plasma and replacement with
physiologic solutions
ESC 2012 research highlights: A slideshow presentationtheheart.org
The European Society of Cardiology (ESC) 2012 Congress took place in Munich, Germany from August 25 through August 29, 2012. Key trials presented at the sessions include: WOEST, ALTITUDE, FAME II, TRILOGY ACS, ACCESS EU,PURE, GARY. IABP SHOCK II, PARAMOUNT and DeFACTO
Austin Journal of Clinical Cardiology is an open access, peer reviewed, scholarly journal dedicated to publish articles in all areas of cardiology and angiology. The aim of the journal is to provide a forum for cardiologists, researchers, physicians, and other health professionals to find most recent advances in the areas of cardiology and cardiovascular diseases.
Austin Journal of Clinical Cardiology accepts original research articles, review articles, case reports, clinical images and rapid communication on all the aspects of cardiology and circulatory system.
Austin Journal of Clinical Cardiology strongly supports the scientific upgradation and fortification in related scientific research community by enhancing access to peer reviewed scientific literary works. Austin Publishing Group also brings universally peer reviewed journals under one roof thereby promoting knowledge sharing, mutual promotion of multidisciplinary science.
Austin Journal of Clinical Cardiology is an open access, peer reviewed, scholarly journal dedicated to publish articles in all areas of cardiology and angiology
Presentación realizada con datos e imágenes obtenidas de la página "The Big Picture", una iniciativa de "The Boston Globe".
Traducida al español, con avance automático y con música.
Consenso Ada Easd 2008 Para El Manejo De La Diabetes Tipo 2
Risk Of Adverse Outcomes Associated With Concomitant Use Of Clopidogrel And Proton Pump Inhibitors
1. Risk of Adverse Outcomes Associated With
Concomitant Use of Clopidogrel and Proton Pump
Inhibitors Following Acute Coronary Syndrome
Online article and related content
P. Michael Ho; Thomas M. Maddox; Li Wang; et al.
current as of March 9, 2009.
JAMA. 2009;301(9):937-944 (doi:10.1001/jama.2009.261)
http://jama.ama-assn.org/cgi/content/full/301/9/937
Supplementary material JAMA Report Video
http://jama.ama-assn.org/cgi/content/full/301/9/937/DC1
Contact me if this article is corrected.
Correction
This article has been cited 2 times.
Citations
Contact me when this article is cited.
Topic collections Cardiovascular System; Prognosis/ Outcomes; Cardiovascular Disease/ Myocardial
Infarction; Drug Therapy; Adverse Effects
Contact me when new articles are published in these topic areas.
Subscribe Email Alerts
http://jama.com/subscribe http://jamaarchives.com/alerts
Permissions Reprints/E-prints
permissions@ama-assn.org reprints@ama-assn.org
http://pubs.ama-assn.org/misc/permissions.dtl
Downloaded from www.jama.com by guest on March 9, 2009